Evidence map›Paper›PMID 42654125›Full record

ArticlePharmaceutics2026

Bioequivalence, Food-Effect Assessment and Exploratory IVIVC of Two Extended-Release Tamsulosin 0.4 mg Formulations in Healthy Mexican Subjects.

Omar Emmanuel Hernández Piña, Alberto Martínez Muñoz, Erika Gabriela Guido Ávila, Abraham Escobedo-Moratilla, Porfirio de la Cruz Cruz, José Trinidad Pérez-Urizar

Abstract read
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Omar Emmanuel Hernández PiñaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Mexico City C.P. 05348, Mexico.
Alberto Martínez MuñozEscuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón, Esq. Plan de San Luis S/N, Casco de Santo Tomás, Miguel Hidalgo, Mexico City C.P. 11340, Mexico.ORCID 0000-0002-7503-2328
Erika Gabriela Guido ÁvilaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Mexico City C.P. 05348, Mexico.
Abraham Escobedo-MoratillaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Mexico City C.P. 05348, Mexico.ORCID 0000-0003-4676-1625
Porfirio de la Cruz CruzDoctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM), Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 550, Col. Lomas 2da. Sección, San Luis Potosí C.P. 78210, Mexico.
José Trinidad Pérez-UrizarFacultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava No. 6, Zona Universitaria, San Luis Potosí C.P. 78210, Mexico.ORCID 0000-0003-0642-0033

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

benign prostatic hyperplasiabioequivalencedose dumpingextended-releasein vitro–in vivo correlationpharmacokineticstamsulosin

Identifiers

PMID42654125
PMCPMC13517056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.